MedPath

Glucosamine

Generic Name
Glucosamine
Drug Type
Small Molecule
Chemical Formula
C6H13NO5
CAS Number
3416-24-8
Unique Ingredient Identifier
N08U5BOQ1K

Overview

Osteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation. Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional benefits to nonsteroidal anti-inflammatory drugs treating the painful symptoms of OA. Glucosamine is commonly used over the counter as a treatment for arthritic joint pain, although its acceptance as a medical therapy varies due to contradictory and findings with unclear clinical significance during clinical trials. It is currently not approved as a prescription product by the FDA, but is widely available over the counter.

Background

Osteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation. Treatment with chondroprotective drugs, such as glucosamine sulfate may offer additional benefits to nonsteroidal anti-inflammatory drugs treating the painful symptoms of OA. Glucosamine is commonly used over the counter as a treatment for arthritic joint pain, although its acceptance as a medical therapy varies due to contradictory and findings with unclear clinical significance during clinical trials. It is currently not approved as a prescription product by the FDA, but is widely available over the counter.

Indication

Glucosamine is generally used over the counter in the symptomatic treatment of osteoarthritis and joint pain, frequently combined with chondroitin sulfate and/or ibuprofen.

Associated Conditions

  • Back pain
  • Joint Pain
  • Osteoarthritis (OA)
  • Osteoarthritis of the Knee
  • Articular inflammation

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/01/11
Phase 2
Completed
2022/02/14
N/A
Completed
2022/01/28
Not Applicable
Recruiting
2019/05/03
Phase 3
Withdrawn
Eurofarma Laboratorios S.A.
2019/04/11
N/A
Completed
2018/11/16
Phase 4
Completed
2018/10/23
Phase 2
Completed
2017/06/28
N/A
UNKNOWN
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2016/08/08
Phase 4
Completed
2016/07/13
Phase 3
Completed
Eurofarma Laboratorios S.A.

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Home Aide Diagnostics, Inc.
69379-285
TOPICAL
5 g in 100 g
3/9/2015

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Glucosamine Sulfate Powder
H20150347
化学药品
散剂
6/19/2020
Glucosamine Sulfate Powder
国药准字HJ20150347
化学药品
散剂
4/29/2025
Glucosamine Sulfate Effervescent Tablets
国药准字H20090310
化学药品
片剂
7/29/2019
Glucosamine Sulfate Tablets
国药准字H20041317
化学药品
片剂
2/23/2020
Glucosamine Sulfate Granules
国药准字H20090077
化学药品
颗粒剂
7/13/2023
Glucosamine Potassium Sulfate Tablets
国药准字H20051759
化学药品
片剂
8/5/2020
Glucosamine Hydrochloride Granules
国药准字H20140004
化学药品
颗粒剂
7/6/2023
Glucosamine Hydrochloride Granules
国药准字H20090094
化学药品
颗粒剂
8/11/2023
Glucosamine Hydrochloride Capsules
国药准字H20173212
化学药品
胶囊剂
2/17/2022
Glucosamine Hydrochloride Capsules
国药准字J20140166
N/A
胶囊剂
10/14/2019

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
GLUCOSAMINE POWDER FOR ORAL SOLUTION 1.5G/SACHET
N/A
N/A
N/A
3/23/2009
© Copyright 2025. All Rights Reserved by MedPath